Home › Research › Biomarkers
Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice
Beatriz Echeveste, Elena Prieto, Edgar F. Guillén, Adolfo Jimenez, Genoveva Montoya‐Murillo, Rafael Villino, Mario Riverol, Javier Arbizu. European Journal of Nuclear Medicine and Molecular Imaging, 2025-04-20
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Amyloid-PET demonstrated high sensitivity (100% in year 1, 94.67% in year 4) and a high negative predictive value (100% in year 1, 88.24% in year 4). FDG-PET exhibited a high negative predictive value initially (94.59% in year 1), and during follow-up, both specificity (85%) and positive predictive value (88%) increased. The conversion from aMCI to AD had a global mean time of 39.95 months. However, progression to AD was slower in amyloid-negative patients versus amyloid-positive patients (75.07 [CI 56.54-81] vs. 32.59 months [CI 20.56-40.74] months). Taking both tests together, the time to conversion was faster in A+/N + versus A+/N- patients (27.79 [CI 20.40-33.21] vs. 37.38 [CI 20.73-48.26] months). Among patients with aMCI, those with a positive Amyloid-PET and an AD pattern on FDG-PET progressed to dementia significantly earlier versus those with a positive Amyloid-PET only. Using both biomarkers during the initial diagnosis enhances the prediction of short-term conversion. CLINICAL TRIAL NUMBER: Not applicable. It is not a clinical trial.
What this study adds
Evidence grade: Low
The record lists 145 participants. Combining amyloid and FDG PET improved prediction of short-term conversion from mild cognitive impairment to Alzheimer's disease, with faster conversion in those positive on both scans. Reported effect size: 94.67%; 88.24%; 94.59%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Echeveste, B., Prieto, E., Guillén, E. F., Jimenez, A., Montoya‐Murillo, G., Villino, R., et al. (2025). Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07275-2
Vancouver
Echeveste B, Prieto E, Guillén EF, Jimenez A, Montoya‐Murillo G, Villino R, et al. Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07275-2. PMID: 40257609.
BibTeX
@article{echeveste2025-40257609,
author = {Echeveste, Beatriz and Prieto, Elena and Guillén, Edgar F. and Jimenez, Adolfo and Montoya‐Murillo, Genoveva and Villino, Rafael and Riverol, Mario and Arbizu, Javier},
title = {{Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice}},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07275-2},
pmid = {40257609},
url = {https://doi.org/10.1007/s00259-025-07275-2}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Amyloid-PET demonstrated high sensitivity (100% in year 1, 94.67% in year 4) and a high negative predictive value (100% in year 1, 88.24% in year 4).
- FDG-PET exhibited a high negative predictive value initially (94.59% in year 1), and during follow-up, both specificity (85%) and positive predictive value (88%) increased.
- The conversion from aMCI to AD had a global mean time of 39.95 months.
- However, progression to AD was slower in amyloid-negative patients versus amyloid-positive patients (75.07 [CI 56.54-81] vs. 32.59 months [CI 20.56-40.74] months).
- Taking both tests together, the time to conversion was faster in A+/N + versus A+/N- patients (27.79 [CI 20.40-33.21] vs. 37.38 [CI 20.73-48.26] months).
Why it matters
Combining amyloid and FDG PET improved prediction of short-term conversion from mild cognitive impairment to Alzheimer's disease, with faster conversion in those positive on both scans. This is a prognostic finding and does not test any treatment or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants145
- Effect size94.67%; 88.24%; 94.59%
- Evidence strengthLow
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (European Journal of Nuclear Medicine and Molecular Imaging) |
| Journal's citation record | 2 / 4 | European Journal of Nuclear Medicine and Molecular Imaging: journal h-index 224 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 145 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 9 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 5.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 9 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Javier Arbizu: h-index 44 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Clinica Universidad de Navarra: institution h-index 435 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40257609) |
| Free to read | 2 / 2 | Free to read |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1007/s00259-025-07275-2
- PubMed: 40257609
- Original source →
- Free full text: European Journal of Nuclear Medicine and Molecular Imaging →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Biomarkers from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.